// App-Quantinova.ai

1017 : Minimal Important Difference (MID), Minimal Detectable Change (MDC), and Disease Activity Thresholds for Two Novel Composite Instruments (3VAS, 4VAS) in Patients with Psoriatic Arthritis: Pooled Analysis of Three Phase 3 Studies

Researchers

Presenter

  • William Tillett

Principal Investigators

  • Laura Coates

  • Marijn Vis

  • Joseph Merola

  • Enrique R Soriano

  • Michelle Perate

  • May Shawi

  • Miriam Zimmermann

  • Emmanouil Rampakakis

  • Mohamed Sharaf

  • Peter Nash

  • Philip Helliwell

Medical Centers

  • Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

  • Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences,, Oxford University Hospitals NHS Trust, Oxford, UK, Oxford, United Kingdom

  • Erasmus University Medical Center, Rotterdam, Netherlands

  • Harvard Medical School, Brigham and Women's Hospital, Boston, MA.

  • Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

  • Janssen Scientific Affairs, Horsham, PA

  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA

  • Janssen, Scientific Affairs, LLC, Zug, Switzerland

  • McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada

  • Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates

  • School of Medicine, Griffith University, QLD, Australia, Brisbane, Australia

Locations

  • United Kingdom

  • Netherlands

  • United States

  • Argentina

  • Switzerland

  • Canada

  • United Arab Emirates

  • Australia

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • C-C Motif Chemokine Ligand 22

Drug/Treatment

  • Grace

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved